LIVN
LivaNova PLC · Healthcare · Medical - Devices
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 15.55K | $761,985 | n/a | n/a |
| Q2 2026 | 98 | -4 | 44.19M | $3.62B | +8 | −13 |
| Q1 2026 | 106 | +4 | 47.23M | $2.90B | +11 | −8 |
| Q4 2025 | 101 | +1 | 45.33M | $2.77B | +2 | n/a |
| Q3 2025 | 19 | -1 | 27.90M | $1.46B | n/a | −2 |
| Q2 2025 | 18 | -1 | 26.29M | $1.18B | n/a | −1 |
| Q1 2025 | 16 | +1 | 14.79M | $580.16M | +1 | n/a |
| Q4 2024 | 15 | 0 | 15.31M | $708.67M | +1 | −1 |
| Q3 2024 | 14 | 0 | 15.20M | $798.66M | +1 | −1 |
| Q2 2024 | 14 | n/a | 15.53M | $851.55M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wealth Enhancement Advisory… | 15.55K | +1.2% | $761,985 | 0.0% | ▲ Add | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 289 holders, 58.28M shares, $3.62B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 3.50K sh · $273,032
Director · 2.30K sh · $187,270
Director · 1.65K sh · $131,538
Officer · 2.67K sh · $207,942
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology